Alzheimer's

C2N, Unilabs sign global agreement on early Alzheimer's diagnostics
By LabPulse.com staff writers
C2N and Unilabs have signed a multiyear agreement that will increase access to C2N's Precivity blood tests for the early diagnosis of Alzheimer's disease to Unilabs' testing network on an exclusive basis.
August 8, 2024
Alzheimers Phases Amyloid Social
ALZpath, Roche sign licensing agreement for dementia biomarker
By LabPulse.com staff writers
ALZpath has signed a licensing agreement with Roche for the use of the ALZpath pTau217 antibody to develop and commercialize a diagnostic blood test for Alzheimer's disease that will be offered on the Roche Elecsys platform.
June 12, 2024
Amyloid Plaque Alzheimer2 Social
Quest adds new biomarker test to Alzheimer's portfolio
By LabPulse.com staff writers
Quest Diagnostics has launched a new blood biomarker test as part of its AD-Detect portfolio of blood tests for Alzheimer's disease risk assessment.
April 23, 2024
Amyloid Plaque Alzheimer Social
Roche, Lilly Alzheimer's blood test granted FDA breakthrough device designation
By LabPulse.com staff writers
The Alzheimer's blood test developed through a collaboration between Roche and Lilly has been granted a breakthrough device designation by the U.S. Food and Drug Administration (FDA).
April 11, 2024
Alzheimers Tau Tangles Social
FDA updates draft guidance for Alzheimer's drug development biomarkers
By LabPulse.com staff writers
The U.S. Food and Drug Administration (FDA) has released an updated draft guidance for the use of biomarkers aimed at sponsors and pharmaceutical companies developing drugs intended to treat early Alzheimer's disease.
March 14, 2024
Amyloid Plaque Alzheimer Social
Eisai invests $15M in C2N to increase Alzheimer's test access
By LabPulse.com staff writers
C2N Diagnostics has announced that pharmaceutical company Eisai has agreed to invest up to $15 million in C2N to provide broader access to Alzheimer’s disease tests.
March 6, 2024
Amyloid Plaque Alzheimer2 Social
Alzheimer’s study results show correlation between blood-based biomarkers and amyloid plaques
By LabPulse.com staff writers
The first results from the Bio-Hermes study have been released, showing a strong correlation between several blood-based and digital biomarkers with the presence of amyloid plaques in the brain, a diagnostic hallmark of Alzheimer's disease (AD).
March 1, 2024
Amyloid Plaque Alzheimer2 Social
NHS lacks capacity for Alzheimer’s diagnostics, warn experts
By Matt Limb
Many thousands of patients in the U.K. could miss out on new treatments for Alzheimer’s disease because its National Health Service (NHS) lacks capacity for diagnostic tests, warn experts.
February 14, 2024
Amyloid Plaque Alzheimer2 Social
Blood test for Alzheimer’s shows high accuracy in study
By Matt Limb
Scientists have hailed study results showing the high accuracy of a blood test that “could revolutionize” diagnosis of Alzheimer’s disease.
January 31, 2024
Alzheimers Tau Tangles Social
Study: Focused ultrasound improves Alzheimer’s drug delivery
By Matt Limb
Alzheimer’s disease researchers have reported promising results from using aducanumab infusions combined with focused ultrasound to reduce levels of cerebral amyloid-beta (Aβ) plaques.
January 17, 2024
Amyloid Plaque Alzheimer2 Social
AI-driven method developed to identify therapeutic targets
By Matt Limb
Researchers have developed a method of identifying therapeutic targets for human diseases associated with protein phase separation that they say could be used to discover targets for Alzheimer’s and other neurogenerative diseases.
October 17, 2023
Artificial Intelligence Brain Social
Protein panel improves Alzheimer’s diagnosis, predictions of disease progression
By Nick Paul Taylor
Quantifying certain proteins in cerebrospinal fluid could improve the diagnosis of Alzheimer's disease and prediction of disease progression, according to a paper in Science Translational Medicine.
October 3, 2023
Brain Dementia Leaves Social
Page 1 of 8
Next Page